keyword
MENU ▼
Read by QxMD icon Read
search

RRMS

keyword
https://www.readbyqxmd.com/read/29785523/efficacy-and-safety-of-rituximab-in-relapsing-and-progressive-multiple-sclerosis-a-hospital-based-study
#1
Carmen Alcalá, F Gascón, F Pérez-Miralles, S Gil-Perotín, A Navarré, I Boscá, F Coret, B Casanova
INTRODUCTION: Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). OBJECTIVE: To investigate the effectiveness and safety of rituximab in MS. PATIENTS AND METHODS: Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. RESULTS: A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment...
May 21, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29783973/erythrocyte-microrna-sequencing-reveals-differential-expression-in-relapsing-remitting-multiple-sclerosis
#2
Kira Groen, Vicki E Maltby, Rodney A Lea, Katherine A Sanders, J Lynn Fink, Rodney J Scott, Lotti Tajouri, Jeannette Lechner-Scott
BACKGROUND: There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS) despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheological features. Several studies have identified an abundance of erythrocyte miRNAs and variable profiles associated with disease states, such as sickle cell disease and malaria. The aim of this study was to compare the erythrocyte miRNA profile of relapsing-remitting MS (RRMS) patients to healthy sex- and age-matched controls...
May 21, 2018: BMC Medical Genomics
https://www.readbyqxmd.com/read/29783156/transient-impairment-of-olfactory-threshold-in-acute-multiple-sclerosis-relapse
#3
Gabriel Bsteh, Harald Hegen, Felix Ladstätter, Klaus Berek, Matthias Amprosi, Sebastian Wurth, Michael Auer, Franziska Di Pauli, Florian Deisenhammer, Andreas Lutterotti, Thomas Berger
BACKGROUND: Impairment of olfactory threshold is a feature of early and active relapsing remitting multiple sclerosis (RRMS). It predicts inflammatory disease activity and was reported to be transient. However, the timing of onset and resolve of olfactory threshold impairment remains unclear. OBJECTIVE: To prospectively assess the development of olfactory threshold in acute MS relapse over time in comparison to stable MS patients. METHODS: In a prospective observational design, we measured olfactory threshold by performing the Sniffin' Sticks test (minimum score 0, maximum score 16 reflecting optimal olfactory function) at baseline and after 4, 12 and 24 weeks...
May 18, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29781383/preferential-spinal-cord-volume-loss-in-primary-progressive-multiple-sclerosis
#4
Charidimos Tsagkas, Stefano Magon, Laura Gaetano, Simon Pezold, Yvonne Naegelin, Michael Amann, Christoph Stippich, Philippe Cattin, Jens Wuerfel, Oliver Bieri, Till Sprenger, Ludwig Kappos, Katrin Parmar
BACKGROUND: Little is known on longer term changes of spinal cord volume (SCV) in primary progressive multiple sclerosis (PPMS). OBJECTIVE: Longitudinal evaluation of SCV loss in PPMS and its correlation to clinical outcomes, compared to relapse-onset multiple sclerosis (MS) subtypes. METHODS: A total of 60 MS age-, sex- and disease duration-matched patients (12 PPMS, each 24 relapsing-remitting (RRMS) and secondary progressive MS (SPMS)) were analysed annually over 6 years of follow-up...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29780609/serum-heat-shock-protein-70-levels-as-a-biomarker-for-inflammatory-processes-in-multiple-sclerosis
#5
Patricia Lechner, Dorothea Buck, Lisa Sick, Bernhard Hemmer, Gabriele Multhoff
Background: Inflammatory and neurodegenerative processes are hallmarks of multiple sclerosis (MS). The synthesis of the major stress-inducible heat shock protein 70 (Hsp70) is induced by inflammation. Objective: The purpose of this study is to determine whether Hsp70 in serum can serve as a potential biomarker to distinguish inflammatory and neurodegenerative processes in MS. Methods: Serum was obtained from 94 patients: 26 clinically isolated syndrome (CIS), 40 relapsing-remitting MS (RRMS), 19 secondary progressive MS (SPMS), and nine primary progressive MS (PPMS)...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29780351/cerebral-blood-flow-changes-in-multiple-sclerosis-and-neuromyelitis-optica-and-their-correlations-with-clinical-disability
#6
Xue Zhang, Xi Guo, Ningnannan Zhang, Huanhuan Cai, Jie Sun, Qiuhui Wang, Yuan Qi, Linjie Zhang, Li Yang, Fu-Dong Shi, Chunshui Yu
Distinguishing relapsing-remitting multiple sclerosis (RRMS) and neuromyelitis optica (NMO) is clinically important because they differ in prognosis and treatment. This study aimed to identify perfusion abnormalities in RRMS and NMO and their correlations with gray matter volume (GMV) atrophy and clinical parameters. Structural and arterial spin labeling MRI scans were performed in 39 RRMS patients, 62 NMO patients, and 73 healthy controls. The gray matter cerebral blood flow (CBF) values were voxel-wisely compared among the three groups with and without GMV correction...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29774057/ocrelizumab-a-new-milestone-in-multiple-sclerosis-therapy
#7
REVIEW
Patricia Mulero, Luciana Midaglia, Xavier Montalban
B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and production of autoantibodies directed against myelin. Hence, the use of B cell-depleting monoclonal antibodies as therapy for autoimmune diseases, including MS, has increased in recent years. Previous results with rituximab, the first therapeutic B cell-depleting chimeric monoclonal antibody that showed efficacy in MS clinical trials, encouraged researchers to evaluate the efficacy of a humanized anti-CD20 antibody, ocrelizumab, in MS...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29767815/the-effect-of-glatiramer-acetate-on-retinal-nerve-fiber-layer-thickness-in-patients-with-relapsing-remitting-multiple-sclerosis-a-longitudinal-optical-coherence-tomography-study
#8
Robert Zivadinov, Eleonora Tavazzi, Jesper Hagemeier, Ellen Carl, David Hojnacki, Channa Kolb, Bianca Weinstock-Guttman
BACKGROUND: Optical coherence tomography (OCT) is a technique that allows for the assessment of retinal nerve fiber layer thickness (RNFLT) and total macular volume (TMV), which reflect neuroaxonal integrity within the retina. As such it has been used in multiple sclerosis (MS) to study neurodegeneration. Glatiramer acetate (GA) is a widely used treatment for MS, which is suggested to have a possible neuroprotective role. OBJECTIVE: The aim of this study was to assess RFNLT and TMV changes in relapsing-remitting MS (RRMS) patients who started treatment with GA and were followed for a 24-month period...
May 16, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29766930/measurement-of-the-permeability-perfusion-and-histogram-characteristics-in-relapsing-remitting-multiple-sclerosis-using-dynamic-contrast-enhanced-mri-with-extended-tofts-linear-model
#9
Ping Yin, Hua Xiong, Yi Liu, Shambhu K Sah, Chun Zeng, Jingjie Wang, Yongmei Li, Nan Hong
Objective: To investigate the application value of using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with extended Tofts linear model for relapsing-remitting multiple sclerosis (RRMS) and its correlation with expanded disability status scale (EDSS) scores and disease duration. Materials and Methods: Thirty patients with multiple sclerosis (MS) underwent conventional magnetic resonance imaging (MRI) and DCE-MRI with a 3.0 Tesla MR scanner. An extended Tofts linear model was used to quantitatively measure MR imaging biomarkers...
May 2018: Neurology India
https://www.readbyqxmd.com/read/29764226/oral-disease-modifying-therapies-for-multiple-sclerosis-in-the-middle-eastern-and-north-african-mena-region-an-overview
#10
Dirk Deleu, Boulenouar Mesraoua, Beatriz Canibaño, Gayane Melikyan, Hassan Al Hail, Lubna El-Sheikh, Musab Ali, Hassan Al Hussein, Faiza Ibrahim, Yolande Hanssens
The introduction of new disease-modifying therapies (DMTs) for remitting-relapsing multiple sclerosis (RRMS) have considerably transformed the landscape of therapeutic opportunities for this chronic disabling disease. Unlike injectable drugs, oral DMTs, promote patient satisfaction and increase therapeutic adherence. This article reviews the salient features about the mode of action, efficacy, safety and tolerability profile of approved oral DMTs in RRMS and reviews their place in clinical algorithms in the Middle East and North Africa (MENA) region...
May 15, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29758075/effectiveness-and-safety-of-rituximab-in-multiple-sclerosis-an-observational-study-from-southern-switzerland
#11
Barbara Scotti, Giulio Disanto, Rosaria Sacco, Marilu' Guigli, Chiara Zecca, Claudio Gobbi
BACKGROUND: Despite positive results from phase II and observational studies, Rituximab (RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used off-label. OBJECTIVE: To characterize MS patients treated with RTX and investigate its effectiveness and safety in a clinical practice setting. METHODS: Observational analysis of data collected from MS patients at the Neurocenter of Southern Switzerland. Relapses, EDSS worsening, MRI lesion accrual and "evidence of disease activity" (EDA) status were described by Cox regression...
2018: PloS One
https://www.readbyqxmd.com/read/29754967/white-matter-microstructural-alterations-in-clinically-isolated-syndrome-and-multiple-sclerosis
#12
Jing Huang, Yaou Liu, Tengda Zhao, Ni Shu, Yunyun Duan, Zhuoqiong Ren, Zheng Sun, Zheng Liu, Hai Chen, Huiqing Dong, Kuncheng Li
This study aims to determine whether and how diffusion alteration occurs in the earliest stage of multiple sclerosis (MS) and the differences in diffusion metrics between CIS and MS by using the tract-based spatial statistics (TBSS) method based on diffusion tensor imaging (DTI). Thirty-six CIS patients (mean age ± SD: 34.0 years ± 12.6), 36 relapsing-remitting multiple sclerosis (RRMS) patients (mean age ± SD: 35.0 years ± 9.4) and 36 age- and gender-matched normal controls (NCs) were included in this study...
May 10, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/29754703/progression-of-a-series-of-patients-with-relapsing-remitting-multiple-sclerosis-treated-for-7-years-with-natalizumab-using-the-no-evidence-of-disease-activity-parameter
#13
A Pato Pato, E Costa Arpín, A Rodríguez Regal, I Rodríguez Constenla, I Cimas Hernando, I Muñoz Pousa, L Naya Ríos, J R Lorenzo González, M C Amigo Jorrín, J M Prieto González
INTRODUCTION: The safety and effectiveness of natalizumab in patients with relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in clinical trials. However, due to the limitations of these trials, it is important to know how the condition behaves under long-term clinical practice conditions. OBJECTIVE: To determine the long-term effectiveness of natalizumab in patients with RRMS by means of annual evaluation of the "no evidence of disease activity" (NEDA) parameter, which includes number of relapses, disability (measured with the Expanded Disability Status Scale), and brain MRI parameters...
May 10, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29743290/cerebrospinal-fluid-immunoglobulin-light-chain-ratios-predict-disease-progression-in-multiple-sclerosis
#14
Emma Rathbone, Lindsay Durant, James Kinsella, Antony R Parker, Ghaniah Hassan-Smith, Michael R Douglas, S John Curnow
OBJECTIVE: To determine whether the ratio of cerebrospinal fluid (CSF) immunoglobulin kappa to lambda light chains at time of multiple sclerosis (MS) diagnosis predicts disease progression and whether this was intrinsic to CSF plasmablasts. METHODS: CSF and peripheral blood were obtained from patients undergoing elective diagnostic lumbar puncture and included clinically isolated syndrome (CIS) (n=43), relapsing remitting MS (RRMS; n=50), primary progressive MS (PPMS; n=20) and other neurological disease controls, both inflammatory (ONID; n=23) and non-inflammatory (OND; n=114)...
May 9, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29729524/dysregulation-of-nrxn1-by-mutant-mir8485-leads-to-calcium-overload-in-pre-synapses-inducing-neurodegeneration-in-multiple-sclerosis
#15
Yogita Kattimani, Avinash M Veerappa
OBJECTIVES: To identify Damaging mutations in microRNAs (miRNAs) and 3' untranslated regions (UTRs) of target genes to establish Multiple sclerosis (MS) disease pathway. METHODS: Female aged 16, with Relapsing Remitting Multiple sclerosis (RRMS) was reported with initial symptoms of blurred vision, severe immobility, upper and lower limb numbness and backache. Whole Exome Sequencing (WES) and disease pathway analysis was performed to identify mutations in miRNAs and UTRs...
April 9, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/29722639/efficacy-of-rituximab-in-refractory-rrms
#16
Pierre Durozard, Adil Maarouf, Clémence Boutiere, Aurelie Ruet, Bruno Brochet, Sandra Vukusic, Clarisse Carra-Dalliere, Pierre Labauge, Guillaume Mathey, Marc Debouverie, Caroline Papeix, Elisabeth Maillart, Catherine Lubetzki, Caroline Bensa, Olivier Gout, Claire Giannesini, Bruno Stankoff, Jonathan Ciron, David Brassat, Jean Pelletier, Audrey Rico Lamy, Bertrand Audoin
OBJECTIVE: To investigate the efficacy of rituximab as rescue therapy in patients with relapsing-remitting multiple sclerosis (RRMS) and persistent disease activity confirmed by magnetic resonance imaging (MRI) despite immunosuppressive disease-modifying therapy (DMT). METHODS: In this observational nationwide retrospective multicenter study, we first identified 351 off-label rituximab-treated patients through a cohort of 15,984 RRMS patients. In this group, we identified patients with disease activity prior to rituximab confirmed by MRI (one or more new T2 lesion and/or gadolinium-enhancing lesion) despite immunosuppressive DMT (fingolimod, natalizumab, or mitoxantrone) with a follow-up after rituximab initiation longer than 6 months...
May 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29720872/adherence-to-subcutaneous-interferon-beta-1a-treatment-using-an-electronic-injection-device-a-prospective-open-label-scandinavian-noninterventional-study-the-scansmart-study
#17
Elena Didenko Pedersen, Egon Stenager, J L Vadgaard, M B Jensen, R Schmid, N Meland, G Magnussen, Jette L Frederiksen
Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes. Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction. Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29719400/new-horizons-for-multiple-sclerosis-therapeutics-milestones-in-the-development-of-ocrelizumab
#18
REVIEW
Jessica Frau, Giancarlo Coghe, Lorena Lorefice, Giuseppe Fenu, Eleonora Cocco
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relapsing-remitting (RR) patients. Ocrelizumab (OCR) is the only MS drug that has been approved by the US Food and Drug Administration (FDA) not only for patients with RRMS but also for patients with primary progressive (PP) MS...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29713769/optic-radiations-are-thinner-and-show-signs-of-iron-deposition-in-patients-with-long-standing-remitting-relapsing-multiple-sclerosis-an-enhanced-t-2-weighted-angiography-imaging-study
#19
Chun Zeng, Silin Du, Yongliang Han, Jialiang Fu, Qi Luo, Yayun Xiang, Xiaoya Chen, Tianyou Luo, Yongmei Li, Yineng Zheng
OBJECTIVE: This study aimed to investigate iron deposition and thickness and signal changes in optic radiation (OR) by enhanced T2 * -weighted angiography imaging (ESWAN) in patients with relapsing-remitting multiple sclerosis (RRMS) with unilateral and bilateral lesions or no lesions. METHODS: Fifty-one RRMS patients (42 patients with a disease duration [DD] ≥ 2 years [group Mor], nine patients with a DD < 2 years [group Les]) and 51 healthy controls (group Con) underwent conventional magnetic resonance imaging (MRI) and ESWAN at 3...
April 30, 2018: European Radiology
https://www.readbyqxmd.com/read/29709026/immunophenotypic-characterization-of-csf-b-cells-in-virus-associated-neuroinflammatory-diseases
#20
Yoshimi Enose-Akahata, Shila Azodi, Bryan R Smith, Bridgette Jeanne Billioux, Ashley Vellucci, Nyater Ngouth, Yuetsu Tanaka, Joan Ohayon, Irene Cortese, Avindra Nath, Steven Jacobson
Intrathecal antibody synthesis is a well-documented phenomenon in infectious neurological diseases as well as in demyelinating diseases, but little is known about the role of B cells in the central nervous systems. We examined B cell and T cell immunophenotypes in CSF of patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) compared to healthy normal donors and subjects with the other chronic virus infection and/or neuroinflammatory diseases including HIV infection, multiple sclerosis (MS) and progressive multifocal leukoencephalopathy...
April 2018: PLoS Pathogens
keyword
keyword
33225
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"